EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

YouTube ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò


[SIDDS 2014]

¼­¿ï »ï¼ºµ¿ COEX¿¡¼­ ¿­¸° SIDDS¿¡ Âü¼®ÇÏ¿´½À´Ï´Ù. Á¦ °ü½É»ç´Â ÁÖ·Î ESD ¿´½À´Ï´Ù. ÀÌ»ó±æ ¼±»ý´Ô°ú Àü¼º¿ì ¼±»ý´ÔÀÇ ÁÁÀº °­Àǵµ ÀÖ¾úÁö¸¸, ¿©±â¼­´Â ¿Ü±¹ ¿¬ÀÚ¿Í ¿Ü°úÀÇ»çÀÇ °­ÀǸ¦ ¼Ò°³ÇÕ´Ï´Ù.


1. Longterm outcome of EGC after ESD (µ¿°æ¾Ï¼¾ÅÍ Oda)

Curative resectionÀ̶ó ÇÏ´õ¶óµµ pathological absolute criteria (=guideline indication)ÀÎÁö pathological expanded criteriaÀÎÁö¿¡ µû¶ó follow-up scheduleÀ» ´Ù¸£°Ô ÇÏ°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ½ÇÁ¦·Î ÀüÀÚ°¡ 781¸í, ÈÄÀÚ°¡ 756¸í (ºÐÈ­Çü 713, ¹ÌºÐÈ­Çü 43)À̾ú½À´Ï´Ù.

En bloc resection rate¿Í complete (R0) resectionÀº °¢°¢ 97.8%¿Í 92.9%·Î ³ô¾Ò½À´Ï´Ù.

Curative resectionÀº 78.6%(in patients)·Î »ý°¢º¸´Ù ³·¾Ò½À´Ï´Ù.

Expanded criteria¿¡ ´ëÇÑ pathological curative resection ȯÀÚ Áß submucosal invasionÀÌ ÀÖ¾ú´ø 2¸í¿¡¼­ ¿ø°ÝÀüÀÌ°¡ ÀÖ¾ú´Ù°í ÇÕ´Ï´Ù. ÇѸíÀº ¼ö¼úÀÌ ºÒ°¡´ÉÇÏ¿© Ç×¾ÏÄ¡·á ÈÄ »ç¸ÁÇϼ̰í, ÇѸíÀº ´ÙÇེ·´°Ô ¼ö¼úÇÒ ¼ö ÀÖ¾ú´Ù°í ÇÕ´Ï´Ù. ÀÌ Á¤µµ¸é ¼ö¼úÀÇ risk¸¦ °í·ÁÇÒ ¶§ ³ª»ÚÁö ¾Ê´Ù°í Çؼ®µÇ¾ú½À´Ï´Ù.

Àá±ñ ÁúÀÇÀÀ´äÀ» ÇÏ¿´´Âµ¥¿ä... Oda ¼±»ý´ÔÀ̳ª Àú³ª ¸ðµÎ ESD 5³â ÈÄ¿¡µµ surveillance´Â Áö¼ÓµÇ¾î¾ß ÇÒ °Í °°´Ù´Â ÀÇ°ßÀ̾ú½À´Ï´Ù.


2. The role of surgery in the era of ESD (°¡Å縯´ëÇÐÀÇ ¼Û±³¿µ)

ESD expanded indication¿¡ ´ëÇÏ¿© µé¾î°¡±â Àü, ¼Û±³¿µ ¼±»ý´ÔÀº ÁÙŸ±â ±×¸²À» º¸¿©ÁÖ¾ú½À´Ï´Ù. ¼÷·ÃµÈ Àü¹®°¡´Â Àß °Ç³Î ¼ö ÀÖÁö¸¸, ¾î¶² »ç¶÷Àº ¶³¾îÁú ¼ö ÀÖ´Ù´Â ¼³¸í°ú ÇÔ²²... ¿ì¸® ³»°úÀÇ»çµéÀÌ ÇÏ´Â ÀÏ¿¡ ´ëÇÑ ¿Ü°úÀÇ»çÀÇ ½Ã°¢À» Àß º¸¿©ÁֽŠ¼ÀÀÔ´Ï´Ù. ¿Ü°ú ¼±»ý´ÔµéÀÌ °ÆÁ¤ÇϽÃÁö ¾Êµµ·Ï ³»°ú ÀÇ»çµéÀÌ Á» ´õ ÀßÇؾ߰ڴٴ »ý°¢ÀÔ´Ï´Ù. ü°èÀûÀÎ µ¥ÀÌŸ ¼öÁýÀÌ ±âÁ¸ÀÏ °ÍÀÔ´Ï´Ù.

StandardizationÀÌ Áß¿äÇÏ´Ù°í °­Á¶Çϼ̽À´Ï´Ù. ƯÈ÷ low volume center¿¡¼­µµ ÀÏ°ü¼ºÀÌ ÀÖ¾î¾ß ÇÕ´Ï´Ù. ¿Ü°ú¿¡¼­´Â À§¾Ï ¼ö¼ú¿¡¼­ centerÀÇ case volume°ú lymph node dissectionÀÇ quality°¡ °°´Ù´Â ÀÚ·á°¡ ÀÖ¾ú½À´Ï´Ù. À¯»çÇÑ ÀڷḦ ³»½Ã°æ ÀÇ»çµéµµ ¸¸µé¾î¾ß ÇÑ´Ù´Â »ý°¢ÀÌ µé¾ú½À´Ï´Ù.

Incomplete resectionÀε¥ ¼ö¼úÇÏÁö ¾ÊÀº ȯÀÚÀÇ 5 YSR´Â 80%¿¡ ºÒ°úÇÏ´Ù´Â ÃÖ±Ù Surg EndoscÀÇ ÀڷḦ º¸¿©Áּ̽À´Ï´Ù. Patient safety °üÁ¡¿¡¼­ Á¢±ÙÇØ¾ß ÇÒ °ÍÀÔ´Ï´Ù.

Hybrid therapy¿¡ ´ëÇÑ ±àÁ¤ÀûÀÎ Àü¸ÁÀ» Á¦½ÃÇÏ¿´½À´Ï´Ù. ±×·¸Áö¸¸ Ç×»ó ÁÖÀÇÇØ¾ß ÇÑ´Ù°í °­Á¶Çϼ̽À´Ï´Ù. Á¦°¡ Èï¹Ì·Ó°Ô º» ºÎºÐÀº Transverse metastasis¸¦ º¸ÀÌ´Â °æ¿ì°¡ ÀÖÀ¸¹Ç·Î sentinel nide concept°¡ ¿ÇÁö ¾ÊÀ» ¼ö ÀÖ´Ù°í ÇϽŠºÎºÐÀÔ´Ï´Ù. Transverse metastasis¶õ º´¼Ò´Â ¼Ò¸¸Àε¥ ´ë¸¸ÂÊÀ¸·Î ÀüÀÌÇÏ´Â °æ¿ì ȤÀº ¹Ý´ë °æ¿ì¸¦ ¸»ÇÏ´Â °ÍÀÔ´Ï´Ù (Ann Surg Oncol 2014;21:1090-1098).

¼±»ý´ÔÀÇ °á·Ð ½½¶óÀ̵带 ±Û·Î ¿Å±é´Ï´Ù.

Expansion of indication ...
- Complete, standardized procedure
- Data interpretation, from safety of patients
- Patients want only a single treatment

Alternative treatment ...
- Hybrid treatment converging the incomplete ESD



© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Jun Haeng Lee.